VeriMomDois-je éviter methyl bimatoprost acidate pendant la grossesse ? | VeriMom
H361 (‘suspected of damaging fertility or the unborn child’) is reported for this substance in supplier/EU SDS/C&L‑type entries and the SCCS included methyl bimatoprost acidate among prostaglandin analogues of concern for cosmetic use; animal reproductive studies with bimatoprost show abortion, increased resorptions and post‑natal pup effects at high doses, and the Latisse/Lumigan product label advises caution in pregnancy. These facts support h=2 (suspected). Mechanistically, prostaglandin analogues have demonstrated reproductive/developmental effects in animal studies (m=2). Systemic absorption from topical/ocular application is low but measurable, so exposure from cosmetic topical use is low but real (e=1). Sources: SCCS opinion, FDA/LATISSE label, supplier SDS.
ECHA regulatory hazard statements
- •H361
- •H362
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- methyl bimatoprost acidate est-il sûr pendant la grossesse ?
- H361 (‘suspected of damaging fertility or the unborn child’) is reported for this substance in supplier/EU SDS/C&L‑type entries and the SCCS included methyl bimatoprost acidate among prostaglandin analogues of concern for cosmetic use; animal reproductive studies with bimatoprost show abortion, increased resorptions and post‑natal pup effects at high doses, and the Latisse/Lumigan product label advises caution in pregnancy. These facts support h=2 (suspected). Mechanistically, prostaglandin analogues have demonstrated reproductive/developmental effects in animal studies (m=2). Systemic absorption from topical/ocular application is low but measurable, so exposure from cosmetic topical use is low but real (e=1). Sources: SCCS opinion, FDA/LATISSE label, supplier SDS.
- methyl bimatoprost acidate est-il sûr pendant l'allaitement ?
- Supplier safety data and regulatory/product labels record H362 (may cause harm to breast‑fed children) and state bimatoprost is excreted in milk in animal studies. Given the parent drug is excreted in milk (per product labels) and the substance is classed with H362 in SDSs, h=2 is appropriate. Mechanism evidence (excretion into milk, documented neonatal effects in animal studies) supports m=2. Exposure by topical cosmetic use is low but measurable (e=1). Sources: FDA/LATISSE label, supplier SDSs.
- methyl bimatoprost acidate est-il sûr pour la peau de bébé ?
- Do not increase hazard (h) or mechanism (m) absent infant‑specific data; retain h=2 and m=2 because the substance is a prostaglandin analogue with suspected reproductive/lactation hazards. Increase exposure (e) by +1 for baby skin per instructions because infant skin is more permeable and systemic exposure from topical application is measurable — therefore e=2 for 0–3‑year‑old skin. Sources: SCCS opinion, FDA product label, supplier SDSs.
- Comment VeriMom évalue-t-il methyl bimatoprost acidate ?
- VeriMom évalue methyl bimatoprost acidate à 20/100 (risque élevé) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.
- Quelles sont les alternatives sûres à methyl bimatoprost acidate pendant la grossesse ?
- Consultez notre liste d'alternatives sûres à methyl bimatoprost acidate basée sur une fonction similaire et une classification sans risques connus.
Vérifiez chaque étiquette en 2 secondes
Obtenez VeriMom gratuitement — scannez n'importe quel produit et voyez le score de sécurité grossesse instantanément.
Avis Médical
Ces informations sont fournies à titre éducatif uniquement et ne constituent pas un avis médical. Les scores de sécurité sont basés sur des données accessibles au public et peuvent ne pas refléter tous les risques. Consultez toujours votre professionnel de santé avant d'utiliser tout produit pendant la grossesse ou l'allaitement.